JP2016519933A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519933A5 JP2016519933A5 JP2016513129A JP2016513129A JP2016519933A5 JP 2016519933 A5 JP2016519933 A5 JP 2016519933A5 JP 2016513129 A JP2016513129 A JP 2016513129A JP 2016513129 A JP2016513129 A JP 2016513129A JP 2016519933 A5 JP2016519933 A5 JP 2016519933A5
- Authority
- JP
- Japan
- Prior art keywords
- genetically engineered
- blood cell
- enucleated blood
- engineered enucleated
- erythrocyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000601 blood cell Anatomy 0.000 claims 19
- 210000003743 erythrocyte Anatomy 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 108091005703 transmembrane proteins Proteins 0.000 claims 7
- 102000035160 transmembrane proteins Human genes 0.000 claims 7
- 108010052285 Membrane Proteins Proteins 0.000 claims 6
- 102000018697 Membrane Proteins Human genes 0.000 claims 6
- 210000003617 erythrocyte membrane Anatomy 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102100035716 Glycophorin-A Human genes 0.000 claims 2
- 108091005250 Glycophorins Proteins 0.000 claims 2
- 108091005956 Type II transmembrane proteins Proteins 0.000 claims 2
- 230000015271 coagulation Effects 0.000 claims 2
- 238000005345 coagulation Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019182854A JP6960177B2 (ja) | 2013-05-10 | 2019-10-03 | ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361822071P | 2013-05-10 | 2013-05-10 | |
| US61/822,071 | 2013-05-10 | ||
| PCT/US2014/037554 WO2014183071A2 (en) | 2013-05-10 | 2014-05-09 | In vitro production of red blood cells with sortaggable proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019182854A Division JP6960177B2 (ja) | 2013-05-10 | 2019-10-03 | ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016519933A JP2016519933A (ja) | 2016-07-11 |
| JP2016519933A5 true JP2016519933A5 (enExample) | 2017-06-22 |
| JP6599848B2 JP6599848B2 (ja) | 2019-10-30 |
Family
ID=51867887
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513129A Expired - Fee Related JP6599848B2 (ja) | 2013-05-10 | 2014-05-09 | ソルタギング可能なタンパク質を有する赤血球のｉｎｖｉｔｒｏ生成 |
| JP2019182854A Expired - Fee Related JP6960177B2 (ja) | 2013-05-10 | 2019-10-03 | ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成 |
| JP2021163272A Pending JP2022001063A (ja) | 2013-05-10 | 2021-10-04 | ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019182854A Expired - Fee Related JP6960177B2 (ja) | 2013-05-10 | 2019-10-03 | ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成 |
| JP2021163272A Pending JP2022001063A (ja) | 2013-05-10 | 2021-10-04 | ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10471099B2 (enExample) |
| EP (4) | EP3546485A1 (enExample) |
| JP (3) | JP6599848B2 (enExample) |
| AU (2) | AU2014262474B2 (enExample) |
| ES (1) | ES2901383T3 (enExample) |
| HK (1) | HK1222662A1 (enExample) |
| WO (1) | WO2014183071A2 (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012275390A1 (en) | 2011-06-28 | 2014-01-16 | Whitehead Institute For Biomedical Research | Using sortases to install click chemistry handles for protein ligation |
| EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| EP3546485A1 (en) | 2013-05-10 | 2019-10-02 | Whitehead Institute for Biomedical Research | In vitro production of red blood cells with sortaggable proteins |
| AU2014262469B2 (en) | 2013-05-10 | 2019-11-14 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| ES2670983T3 (es) | 2013-11-07 | 2018-06-04 | Editas Medicine, Inc. | Métodos y composiciones relacionados con CRISPR con ARNg rectores |
| WO2015073746A2 (en) | 2013-11-13 | 2015-05-21 | Whitehead Institute For Biomedical Research | 18f labeling of proteins using sortases |
| WO2015073587A2 (en) * | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| US10869898B2 (en) | 2014-04-01 | 2020-12-22 | Rubius Therapeutics, Inc. | Methods and compositions for immunomodulation |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| US10053683B2 (en) | 2014-10-03 | 2018-08-21 | Whitehead Institute For Biomedical Research | Intercellular labeling of ligand-receptor interactions |
| SG11201704627XA (en) | 2014-12-17 | 2017-07-28 | Hoffmann La Roche | Enzymatic one-pot reaction for double polypeptide conjugation in a single step using sortase |
| JP6800154B2 (ja) | 2014-12-17 | 2020-12-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 結合形成酵素の活性アッセイ |
| WO2016183482A1 (en) * | 2015-05-13 | 2016-11-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
| CN108026560A (zh) | 2015-09-25 | 2018-05-11 | 豪夫迈·罗氏有限公司 | 在低共熔溶剂中使用分选酶的转酰胺反应 |
| EP3353310B1 (en) | 2015-09-25 | 2020-04-29 | H. Hoffnabb-La Roche Ag | Process for producing thioesters employing a sortase a |
| ES2941968T3 (es) | 2015-10-01 | 2023-05-29 | The Whitehead Institute For Biomedical Res | Marcaje de anticuerpos |
| IL294014B2 (en) | 2015-10-23 | 2024-07-01 | Harvard College | Nucleobase editors and uses thereof |
| CA3009063A1 (en) | 2016-01-11 | 2017-07-20 | Rubius Therapeutics, Inc. | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
| WO2017124102A1 (en) | 2016-01-14 | 2017-07-20 | North Carolina State University | Glucose responsive insulin delivery compositions and methods |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| CN109804066A (zh) | 2016-08-09 | 2019-05-24 | 哈佛大学的校长及成员们 | 可编程cas9-重组酶融合蛋白及其用途 |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| CN110214180A (zh) | 2016-10-14 | 2019-09-06 | 哈佛大学的校长及成员们 | 核碱基编辑器的aav递送 |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| JP2019536793A (ja) | 2016-12-02 | 2019-12-19 | ルビウス セラピューティクス， インコーポレイテッド | 固形腫瘍に浸透させるための細胞系に関連する組成物および方法 |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| US11020435B2 (en) | 2017-02-17 | 2021-06-01 | Rubius Therapeutics, Inc. | Functionalized erythroid cells |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| WO2018165631A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Cancer vaccine |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| EP3654992A1 (en) | 2017-07-19 | 2020-05-27 | Rubius Therapeutics, Inc. | Compositions and methods related to multimodal therapeutic cell systems for cardiometabolic disease |
| US20200172868A1 (en) | 2017-07-19 | 2020-06-04 | Rubius Therapeutics, Inc. | Compositions and methods related to multimodal therapeutic cell systems for infectious disease |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| CN111491655A (zh) | 2017-08-07 | 2020-08-04 | 加利福尼亚大学董事会 | 用于生成安全细胞治疗剂的平台 |
| US10960071B2 (en) | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| EP3672602A1 (en) | 2017-08-22 | 2020-07-01 | Rubius Therapeutics, Inc. | Lipid nanoparticle methods and compositions for producing engineered erythroid cells |
| WO2019040649A1 (en) * | 2017-08-23 | 2019-02-28 | Whitehead Institute For Biomedical Research | PRODUCTION OF REDUCED GLOBULATES AND USES THEREOF |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| CN111757937A (zh) | 2017-10-16 | 2020-10-09 | 布罗德研究所股份有限公司 | 腺苷碱基编辑器的用途 |
| WO2019090148A2 (en) | 2017-11-03 | 2019-05-09 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems for tumor growth inhibition |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| WO2019126818A1 (en) * | 2017-12-23 | 2019-06-27 | Rubius Therapeutics, Inc. | Artificial antigen presenting cells and methods of use |
| US20190201548A1 (en) | 2017-12-29 | 2019-07-04 | Rubius Therapeutics, Inc. | Gene editing and targeted transcriptional modulation for engineering erythroid cells |
| US20190330591A1 (en) | 2018-01-10 | 2019-10-31 | Rubius Therapeutics, Inc. | Amplifiable rnas for therapeutic cell systems |
| WO2019173798A1 (en) | 2018-03-08 | 2019-09-12 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating cancer and infectious diseases |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| JP2022513312A (ja) * | 2018-09-21 | 2022-02-07 | シティー・ユニバーシティー・オブ・ホンコン | 表面修飾細胞外小胞 |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| WO2020117852A1 (en) | 2018-12-03 | 2020-06-11 | Rubius Therapeutics, Inc. | Artificial antigen presenting cells including hla-e and hla-g molecules and methods of use |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| BR112021016451A2 (pt) * | 2019-02-20 | 2021-11-09 | Rubius Therapeutics Inc | Célula eritroide projetada incluindo polipeptídeos apresentadores de antígeno carregáveis e métodos de uso |
| CA3130488A1 (en) | 2019-03-19 | 2020-09-24 | David R. Liu | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| TW202106315A (zh) | 2019-04-26 | 2021-02-16 | 美商盧比亞斯治療公司 | 包括去核類紅血球之組成物 |
| AU2020283752A1 (en) | 2019-05-24 | 2021-12-23 | Rubius Therapeutics, Inc. | Methods of generating enucleated erythroid cells |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| JP2023500325A (ja) | 2019-11-04 | 2023-01-05 | ルビウス セラピューティクス， インコーポレイテッド | タウリンまたはヒポタウリンを使用して除核赤芽球細胞を生成する方法 |
| WO2021092052A1 (en) | 2019-11-04 | 2021-05-14 | Rubius Therapeutics, Inc. | Methods of generating enucleated erythroid cells using myo-inositol |
| US20230050813A1 (en) | 2020-01-13 | 2023-02-16 | Carmine Therapeutics Pte. Ltd. | Nucleic acid loaded red blood cell extracellular vesicles |
| JP2023512712A (ja) * | 2020-02-07 | 2023-03-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 除核細胞をバイオ操作するための方法および使用 |
| US20210246426A1 (en) | 2020-02-10 | 2021-08-12 | Rubius Therapeutics, Inc. | Engineered Erythroid Cells Including HLA-G Polypeptides and Methods of Use Thereof |
| WO2021185359A1 (en) * | 2020-03-20 | 2021-09-23 | Westlake Therapeutics (Hangzhou) Co. Limited | Modified red blood cells and uses thereof for delivering agents |
| WO2021226558A1 (en) | 2020-05-08 | 2021-11-11 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| CA3178252A1 (en) | 2020-05-11 | 2021-11-18 | Erytech Pharma | Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof |
| WO2022089605A1 (en) * | 2020-10-30 | 2022-05-05 | Westlake Therapeutics (Hangzhou) Co. Limited | Modified red blood cells and uses thereof for delivering agents |
| EP4243839A1 (en) | 2020-11-13 | 2023-09-20 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| TW202241471A (zh) | 2021-01-08 | 2022-11-01 | 美商盧比亞斯治療公司 | 提高個體中NKp30陽性淋巴球的方法及其用途 |
| WO2022150578A1 (en) | 2021-01-08 | 2022-07-14 | Rubius Therapeutics, Inc. | Methods of treating a tumor in a human subject |
| JP2024505818A (ja) * | 2021-01-29 | 2024-02-08 | ナショナル ユニバーシティ オブ シンガポール | 細胞表面を修飾された赤血球及びその調製方法 |
| WO2022166913A1 (en) * | 2021-02-04 | 2022-08-11 | Westlake Therapeutics (Hangzhou) Co. Limited | Modified red blood cells and uses thereof for treating hyperuricemia and gout |
| WO2022197548A1 (en) | 2021-03-14 | 2022-09-22 | Rubius Therapeutics, Inc. | Methods of increasing nkg2d-positive lymphocytes in a subject and uses thereof |
| WO2022211740A1 (en) | 2021-03-31 | 2022-10-06 | Carmine Therapeutics Pte. Ltd. | Extracellular vesicles loaded with at least two different nucleic acids |
| TW202317179A (zh) | 2021-06-03 | 2023-05-01 | 美商盧比亞斯治療公司 | 在個體中治療ｈｐｖ１６－陽性或ｈｐｖ１６－相關的癌症之方法 |
| US20250276013A1 (en) * | 2021-07-13 | 2025-09-04 | Westlake Therapeutics (Hangzhou) Co. Limited | Cells Modified by Conjugated N-Terminal Glycine and Uses Thereof |
| CN120152732A (zh) * | 2022-10-24 | 2025-06-13 | 西湖生物医药科技(上海)有限公司 | 诱导特异性免疫耐受的组合 |
| WO2024215885A2 (en) * | 2023-04-12 | 2024-10-17 | Cytonus Therapeutics, Inc. | Manufacturing of therapeutic cells |
| WO2025006882A1 (en) * | 2023-06-30 | 2025-01-02 | The Children's Hospital Of Philadelphia | Click chemistry assisted cell surface engineering for restoring lentivirus entry |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834256A (en) | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| US5670132A (en) | 1994-09-20 | 1997-09-23 | Immunomedics, Inc. | Modified radioantibody fragments for reduced renal uptake |
| US5728369A (en) | 1994-10-05 | 1998-03-17 | Immunomedics, Inc. | Radioactive phosphorus labeling of proteins for targeted radiotherapy |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| CA2238434A1 (en) | 1995-12-15 | 1997-06-19 | Systemix, Inc. | Method for obtaining retroviral vector supernatant having high transduction efficiency |
| CA2365523A1 (en) | 1999-04-15 | 2000-10-26 | The Regents Of The University Of California | Identification of sortase gene |
| CA2413538A1 (en) | 2000-07-06 | 2002-01-17 | Bristol-Myers Squibb Pharma Company | Stable radiopharmaceutical compositions and methods for preparation thereof |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US6960473B2 (en) * | 2003-02-27 | 2005-11-01 | Istituto Superiore Di Sanita | In vitro mass production of human erythroid cells from the blood of normal donors and thalassemic patients |
| WO2005051976A2 (en) | 2003-11-20 | 2005-06-09 | Ansata Therapeutics, Inc. | Protein and peptide ligation processes and one-step purification processes |
| US20090098611A1 (en) | 2004-02-27 | 2009-04-16 | Wood David W | Self-cleaving affinity tags and methods of use |
| JP5139799B2 (ja) * | 2004-06-04 | 2013-02-06 | ユニベルシテ ピエール エ マリー キュリー（パリ シズエム） | 赤血球細胞の生産方法 |
| US8398956B2 (en) | 2007-01-11 | 2013-03-19 | Immunomedics, Inc. | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
| CA2691357C (en) | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| US20120034155A1 (en) | 2010-08-03 | 2012-02-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Artificial cells |
| US8211656B2 (en) * | 2008-08-13 | 2012-07-03 | The Invention Science Fund I, Llc | Biological targeting compositions and methods of using the same |
| MX2011002250A (es) | 2008-08-25 | 2011-08-17 | Amplimmune Inc | Antagonistas de muerte celular programada-1 y métodos de uso de los mismos. |
| HUE027525T2 (en) | 2008-08-25 | 2016-11-28 | Amplimmune Inc | PD-1 Antagonist preparations and their use |
| US20100092470A1 (en) | 2008-09-22 | 2010-04-15 | Icb International, Inc. | Antibodies, analogs and uses thereof |
| JP2010115136A (ja) * | 2008-11-12 | 2010-05-27 | Teruyuki Nagamune | Ｎ末端標識膜蛋白質の作製方法、及びｎ末端標識膜蛋白質を表層に有する細胞 |
| WO2010078376A2 (en) | 2008-12-30 | 2010-07-08 | Ventana Medical Systems, Inc. | Fc-specific polymer-conjugated antibodies and their diagnostic use |
| EP2391714B2 (en) | 2009-01-30 | 2019-07-24 | Whitehead Institute for Biomedical Research | Methods for ligation and uses thereof |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2533810B1 (en) | 2010-02-10 | 2016-10-12 | ImmunoGen, Inc. | Cd20 antibodies and uses thereof |
| PT2539441T (pt) * | 2010-02-22 | 2017-01-05 | Assist Publique Hôpitaux De Paris | Meio de cultura de células para o crescimento e diferenciação de células da linhagem hematopoiética |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| EP2593469A4 (en) | 2010-04-20 | 2015-07-15 | Whitehead Biomedical Inst | MODIFIED POLYPEPTIDES AND PROTEINS AND ITS APPLICATION |
| WO2012142659A1 (en) | 2011-04-19 | 2012-10-26 | Baker Idi Heart And Diabetes Institute Holdings Limited | Site-selective modification of proteins |
| AU2012275390A1 (en) * | 2011-06-28 | 2014-01-16 | Whitehead Institute For Biomedical Research | Using sortases to install click chemistry handles for protein ligation |
| CN102559600A (zh) | 2011-12-29 | 2012-07-11 | 上海交通大学医学院 | 一种人工抗原递呈细胞及其在nk细胞扩增中的应用 |
| WO2013132317A1 (en) | 2012-03-07 | 2013-09-12 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
| EP2836507A4 (en) | 2012-04-13 | 2016-08-24 | Whitehead Biomedical Inst | SORTAS-MODIFIED VHH DOMAINS AND USES THEREOF |
| US20140030697A1 (en) | 2012-06-14 | 2014-01-30 | Massachusetts Institute Of Technology | Sortase-mediated modification of viral surface proteins |
| US9267127B2 (en) | 2012-06-21 | 2016-02-23 | President And Fellows Of Harvard College | Evolution of bond-forming enzymes |
| US9511350B2 (en) | 2013-05-10 | 2016-12-06 | Clean Diesel Technologies, Inc. (Cdti) | ZPGM Diesel Oxidation Catalysts and methods of making and using same |
| AU2014262469B2 (en) | 2013-05-10 | 2019-11-14 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| EP3546485A1 (en) | 2013-05-10 | 2019-10-02 | Whitehead Institute for Biomedical Research | In vitro production of red blood cells with sortaggable proteins |
| US10260043B2 (en) | 2013-05-15 | 2019-04-16 | University Of Rochester | Human extensively self-renewing erythroblasts (ESRE) |
| WO2015051188A1 (en) | 2013-10-02 | 2015-04-09 | Washington University | Heterocyclic molecules for biomedical imaging and therapeutic applications |
| US9878045B2 (en) | 2013-10-15 | 2018-01-30 | Regents Of The University Of Minnesota | Triorthogonal reagents for dual protein conjugation |
| WO2015073746A2 (en) | 2013-11-13 | 2015-05-21 | Whitehead Institute For Biomedical Research | 18f labeling of proteins using sortases |
| US10053683B2 (en) | 2014-10-03 | 2018-08-21 | Whitehead Institute For Biomedical Research | Intercellular labeling of ligand-receptor interactions |
| WO2016183482A1 (en) | 2015-05-13 | 2016-11-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
| ES2941968T3 (es) | 2015-10-01 | 2023-05-29 | The Whitehead Institute For Biomedical Res | Marcaje de anticuerpos |
| WO2019040649A1 (en) | 2017-08-23 | 2019-02-28 | Whitehead Institute For Biomedical Research | PRODUCTION OF REDUCED GLOBULATES AND USES THEREOF |
| AU2020283752A1 (en) * | 2019-05-24 | 2021-12-23 | Rubius Therapeutics, Inc. | Methods of generating enucleated erythroid cells |
-
2014
- 2014-05-09 EP EP19171190.2A patent/EP3546485A1/en not_active Withdrawn
- 2014-05-09 AU AU2014262474A patent/AU2014262474B2/en not_active Ceased
- 2014-05-09 EP EP19171188.6A patent/EP3546484B1/en not_active Not-in-force
- 2014-05-09 ES ES19171188T patent/ES2901383T3/es active Active
- 2014-05-09 HK HK16110752.9A patent/HK1222662A1/zh unknown
- 2014-05-09 WO PCT/US2014/037554 patent/WO2014183071A2/en not_active Ceased
- 2014-05-09 US US14/890,241 patent/US10471099B2/en active Active - Reinstated
- 2014-05-09 EP EP19219550.1A patent/EP3693398A1/en not_active Withdrawn
- 2014-05-09 JP JP2016513129A patent/JP6599848B2/ja not_active Expired - Fee Related
- 2014-05-09 EP EP14795167.7A patent/EP2994491A4/en not_active Withdrawn
-
2018
- 2018-03-23 US US15/934,177 patent/US11266695B2/en active Active
-
2019
- 2019-09-16 US US16/572,425 patent/US11992505B2/en active Active
- 2019-10-03 JP JP2019182854A patent/JP6960177B2/ja not_active Expired - Fee Related
- 2019-12-16 AU AU2019283766A patent/AU2019283766B2/en not_active Ceased
-
2021
- 2021-10-04 JP JP2021163272A patent/JP2022001063A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016519933A5 (enExample) | ||
| Yang et al. | High-mobility group box-1 and its role in angiogenesis | |
| SA517380842B1 (ar) | بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام | |
| PH12018502451A1 (en) | Brain delivery protein | |
| WO2014018858A3 (en) | Multimeric fusion protein vaccine and immunotherapeutic | |
| JP2016222689A5 (ja) | 合成ペプチド及び乾燥粉末薬剤輸送システム | |
| WO2013088148A3 (en) | Method of treatment employing therapeutic t cell product from mobilised donors | |
| CN106659777A8 (zh) | 免疫原性组合产品 | |
| PH12013500108A1 (en) | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract | |
| JP2012126742A5 (enExample) | ||
| MX2020006822A (es) | Proteinas de fusion de anticuerpo de un solo dominio-citosina desaminasa. | |
| EA201591213A1 (ru) | Вакцины против вируса гепатита b | |
| AR056245A1 (es) | Membranas virales reconstituidas funcionales que contienen un coadyuvante | |
| WO2013076580A3 (en) | Recombinant proteins and their therapeutic uses | |
| MX387764B (es) | Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos. | |
| WO2015140172A3 (en) | A medicament for use in a method of inducing or extending a cellular cytotoxic immune response | |
| EA201891639A1 (ru) | Аминокислотные и пептидные конъюгаты и способ конъюгации | |
| MX2019001136A (es) | Partículas similares a virus con recubrimiento de alta densidad para inducir la expresión de anticuerpos. | |
| JP2016508143A5 (enExample) | ||
| WO2015095167A3 (en) | Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon | |
| JP2018023397A5 (enExample) | ||
| RU2019113989A (ru) | Лекарственное средство | |
| EA202090319A1 (ru) | Пептидные конъюгаты, способ конъюгации и их использование | |
| WO2018175740A8 (en) | Anti-tmeff1 antibodies and antibody drug conjugates | |
| EA201400216A1 (ru) | Консервирование биологических продуктов, в частности вакцин, с применением вакуума |